Sanofi India Limited has informed the Exchange regarding Appointment of Mrs. Rajani Kesari as Non- Executive Independent Director of the company w.e.f. April 01, 2026.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India's board approved audited results for FY ended Dec 31, 2025. Revenue from continuing operations fell to ₹18,374 crore from ₹20,132 crore, mainly because export sales dropped by ₹1,481 million after the expected end of its Zentiva contract. Profit before tax from continuing operations rose slightly to ₹4,447 crore from ₹4,314 crore, while total profit for the year was ₹3,267 crore versus ₹4,135 crore (FY24 included ₹998 crore from discontinued Consumer Healthcare operations after the demerger). Statutory auditors Price Waterhouse issued an unmodified opinion. The board recommended a final dividend of ₹48 per share, taking total FY25 dividend to ₹123 per share (alongside the ₹75 interim dividend). On the board, Mrs. Rajani Kesari joins as Independent Director for 5 years from April 1, 2026, and Ms. Sudipta Chakraborty joins as Whole-time Director and Key Managerial Personnel for 3 years from March 1, 2026. Non-Executive Director Mr. Rodolfo Hrosz resigned citing other commitments, effective Feb 28, 2026.
The revenue decline from the Zentiva contract loss is a watch item, but earnings and margins held up and the ₹123 total dividend signals continued shareholder returns. Board changes appear routine — an orderly transition with a new Independent Director and Whole-time Director replacing a resigning Non-Executive Director — and are unlikely to move the stock on their own.